The Coronavirus medicine being already developed? | Wikitrends

The Coronavirus Medicine

Amid growing infection of the corona virus and a need for Coronavirus medicine , scientists around the world are researching for its medicine and vaccine. Meanwhile, the first definitive drug for the treatment of coronavirus treatment has arrived in the Indian market. Glenmark Pharmaceuticals Company has received the permission to manufacture and market the antiviral drug Favipiravir for Covid-19. The company will manufacture this drug under the name FaviFlu. The antiviral drug Favipiravir is manufactured as Faviflu for the treatment of early corona patients.

This drug has emerged as a major hope in the Corona epidemic. Let’s know, 10 important things including the dosage and price of this medicine.

Medicine for whom?

Coronavirus medicine
©
Moneycontrol

The company has said that apart from patients with minor infections who are also corona patients suffering from diabetes or heart disease, this medicine can also be given. This drug is available in tablet form and hence it is very convenient when there is extra pressure on the hospital system.

Also watch :- Karvaan – D.I.I.B | Lyrical Video | Prod by Op Beatz | Dspd Production

Appropriate Drug dose

The company says that the faviflu drug is an advanced form of favipiravir drug for the treatment of corona, which has been approved. This medicine will be available only on the advice of a doctor. On the first day, two doses of 1800 mg will have to be taken, and after that, two doses of 800 mg will have to be taken for 14 days.

Also read

Drug price

According to Glenmark Pharmaceuticals, the drug will be available in 200 mg tablets. It will have 34 tablets in one leaf, which will cost Rs 3,500. That is, a tablet will cost Rs 103. It is a type of antiviral medicine.

Coronavirus medicine
©
The Peninsula Qatar

Drug production

Regarding the production of the drug, the company said that it would be able to provide Faviflu to 82,500 patients in the first month, according to the requirement of minimum two leaves per patient. The company said that the company is eyeing the state of the epidemic and the company will increase production according to the country’s healthcare sector.

Where is the medicine being made?

The company is producing an active pharmaceutical ingredient (API) for this drug at its Ankleshwar plant. At the same time, the formulation is being produced at the Baddi plant in Himachal Pradesh. Apart from hospitals, this drug will also be available through retail channels.

Drug supply

On the question of whether an alliance will be made with hospitals for the supply of this medicine, the company said that at present, our priority is to manufacture this medicine to the patients. The company will definitely consider supporting the private and government healthcare sector according to time and need.

Great hope

The company said that it has received permission from the Drug Controller General of India (DGCI) to manufacture and market the drug i.e. The company’s chairman-cum-managing director Glenn  said, “This approval has come at a time when the corona virus cases in India are increasing more rapidly than before.”

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: